Abbott (ABT) closed the most recent trading day at $113.70, moving -0.39% from the previous trading session.
Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the United States.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Dividend stocks are all-weather investments for buy-and-hold investing because they can help reduce portfolio volatility while generating income. Buying them when they are down and building a solid position is the recipe for market-beating total returns over time.
Abbott (ABT) reachead $117.63 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run.
Abbott's diversified growth, driven by innovative medical devices and established pharmaceuticals, positions it well for long-term success and market outperformance. Despite legal challenges and post-pandemic headwinds, Abbott's robust earnings growth and solid dividend profile make it an attractive investment. Abbott's strong innovation pipeline, including advancements in CGM systems, supports its market share gains and growth outlook.
Dividend stocks that grow their payouts can be ideal income sources for investors to buy and hold. The stocks listed here have profitable and predictable businesses, making them safe options to invest in.
These two companies have been leaders in the healthcare industry for a long time. Both have solid underlying businesses and belong in the group of Dividend Kings.
In the latest trading session, Abbott (ABT) closed at $117.11, marking a +0.58% move from the previous day.
ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.